China can sell (at a profit) >99.8% pure tirzepatide, semaglutide, and retatrutide for <$3/weekly dose. This supply ends up at compounding pharmacies like Hims/Hers, but sometimes more directly to consumers through gray/black markets.

Another way to check if the marginal cost of production contributes to the cost of the drug is to compare the price of injectable semaglutide (~$1200) for around 10mg/month, to the price of oral semaglutide (Rybelsus), which is also (~$1,000) for around 420mg/month. That indicates that the cost of manufacturing semaglutide does not significantly contribute to the cost of the FDA-approved drug.